While the "Moonshot" aims at the future, a "groundshot" initiative could address the issues facing cancer patients right now by making better use of services that are already available.
The FLT3 inhibitor, taken during chemotherapy and continued as a single agent for up to 3 years, significantly improved survival compared with standard chemotherapy.
For patients with acute myeloid leukemia, treatment with decitabine prior to stem cell transplantation had similar overall survival and much less toxicity compared with intensive chemotherapy.